Literature DB >> 10329677

Studies with a growth hormone antagonist and dual-fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signaling.

M Maamra1, J Finidori, S Von Laue, S Simon, S Justice, J Webster, S Dower, R Ross.   

Abstract

UNLABELLED: We have investigated trafficking of two negative regulators of growth hormone receptor (GHR) signaling: a human, truncated receptor, GHR1-279, and a GH antagonist, B2036. Fluorescent-labeled growth hormone (GH) was rapidly internalized by the full-length GHR, with >80% of the hormone internalized within 5 min of exposure to GH. In contrast, <5% of labeled GH was internalized by cells expressing truncated GHR1-279. Using another truncated receptor, GHR1-317 fused to enhanced green fluorescent protein (EGFP), we have exploited fluorescence energy transfer to monitor the trafficking of ligand-receptor complexes. The data confirmed that internalization of this truncated receptor is very inefficient. It was possible to visualize the truncated GHR1-317-EGFP packaged in the endoplasmic reticulum, its rapid movement in membrane bound vesicles to the Golgi apparatus, and subsequent transport to the cell membrane. The GH antagonist, B2036, blocked Jak2-Stat5-mediated GHR signaling but was internalized with a similar time course to native GH. THE
RESULTS: 1) demonstrate the rapid internalization of GH when studied under physiological conditions; 2) confirm the hypothesis that internalization of cytoplasmic domain truncated human GHRs is very inefficient, which explains their dominant negative action; and 3) show that the antagonist action of B2036 is independent of receptor internalization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329677     DOI: 10.1074/jbc.274.21.14791

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

Authors:  A Bowie; E Kiss-Toth; J A Symons; G L Smith; S K Dower; L A O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells.

Authors:  Timothy M Piazza; Juu-Chin Lu; Kristopher C Carver; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2008-12-04

3.  Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2.

Authors:  K C Leung; N Doyle; M Ballesteros; K Sjogren; C K W Watts; T H Low; G M Leong; R J M Ross; K K Y Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

4.  Expression of a glycosylphosphatidylinositol-anchored ligand, growth hormone, blocks receptor signalling.

Authors:  François Guesdon; Yahia Kaabi; Aiden H Riley; Ian R Wilkinson; Colin Gray; David C James; Peter J Artymiuk; Jon R Sayers; Richard J Ross
Journal:  Biosci Rep       Date:  2012-12       Impact factor: 3.840

5.  CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.

Authors:  Borja Guerra; Patricia Martín-Rodríguez; Juan Carlos Díaz-Chico; Grant McNaughton-Smith; Sandra Jiménez-Alonso; Idaira Hueso-Falcón; Juan Carlos Montero; Rosa Blanco; Javier León; Germán Rodríguez-González; Ana Estévez-Braun; Atanasio Pandiella; Bonifacio Nicolás Díaz-Chico; Leandro Fernández-Pérez
Journal:  Oncotarget       Date:  2017-05-02

6.  Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation.

Authors:  Jürgen Klammt; David Neumann; Evelien F Gevers; Shayne F Andrew; I David Schwartz; Denise Rockstroh; Roberto Colombo; Marco A Sanchez; Doris Vokurkova; Julia Kowalczyk; Louise A Metherell; Ron G Rosenfeld; Roland Pfäffle; Mehul T Dattani; Andrew Dauber; Vivian Hwa
Journal:  Nat Commun       Date:  2018-05-29       Impact factor: 14.919

Review 7.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

8.  Developmental Adaptive Immune Defects Associated with STAT5B Deficiency in Three Young Siblings.

Authors:  Corinne L Foley; Sareea S Al Remeithi; Christopher T Towe; Andrew Dauber; Philippe F Backeljauw; Leah Tyzinski; Ashish R Kumar; Vivian Hwa
Journal:  J Clin Immunol       Date:  2020-10-22       Impact factor: 8.317

9.  A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells.

Authors:  Patricia Martín-Rodríguez; Borja Guerra; Idaira Hueso-Falcón; Haidee Aranda-Tavío; Juan Díaz-Chico; José Quintana; Francisco Estévez; Bonifacio Díaz-Chico; Angel Amesty; Ana Estévez-Braun; Leandro Fernández-Pérez
Journal:  Front Pharmacol       Date:  2019-01-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.